

## References

1. Vynichuk SM, Fartushna OE. *Mezhdunarodnyi nevrolohicheskyi zhurnal – Intern Neurol J* 2009;7(29):32–38 (in Ukr).
2. Mytchenko OI, Romanov VU, Yanovska KO. *Ukrainskyi kardiologichnyi zhurnal – Ukr Cardiol J* 2011;4:6–8 (in Ukr).
3. Doerschug KC, Delsing AS, Schmidt GA. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. *Crit Care* 2010;14:R24.
4. Drenger B, Manuel L. Fontes Patterns of Use of Perioperative Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. *Circulation* 2012;126:261–269.
5. Leschka S, Scheffel H, Desbiolles L. Combining dual-source computed tomography coronary angiography and calcium scoring: added value for the assessment of coronary artery disease. *Heart* 2008;94:1154–1161.
6. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin–angiotensin systems. *Physiol Rev* 2006;86:747–803.
7. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. *J Am Coll Cardiol* 11.07.2011.
8. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. *J Invasive Cardiol* 2001 Feb;13(2):93–7.